Pancuronium

Nondepolarizing Neuromuscular Blocker — MUSCULO-SKELETAL SYSTEM

Key facts

Pancuronium is an ofp drug in the Nondepolarizing Neuromuscular Blocker class catalogued in DrugCentral. It was first approved by the FDA in 1972. DrugCentral lists 3 molecular targets, including CHRNB2|CHRNA4, CHRNA1|CHRNB1|CHRND and CHRNA1|CHRNG|CHRNB1|CHRND. Recorded indications include General anesthesia, Muscle relaxation, function and Skeletal Muscle Relaxation for Endotracheal Intubation.

• Approval status: ofp (first approved 1972 by the FDA).
• Drug class: Nondepolarizing Neuromuscular Blocker.
• Molecular targets: CHRNB2|CHRNA4, CHRNA1|CHRNB1|CHRND and CHRNA1|CHRNG|CHRNB1|CHRND (3 listed in DrugCentral).
• Indications: General anesthesia, Muscle relaxation, function and Skeletal Muscle Relaxation for Endotracheal Intubation.
• ATC code: M03AC01 (Other quaternary ammonium compounds).
• Molecular formula: C35H60N2O4; molecular weight 572.87 g/mol.

Indications & contraindications

Drug–disease relationships curated by DrugCentral (OMOP / SNOMED concepts).

Indications (3)

• General anesthesia
• Muscle relaxation, function
• Skeletal Muscle Relaxation for Endotracheal Intubation

Contraindications (14)

• Acidosis
• Asthenia
• Body fluid retention
• Carcinomatosis
• Complete Biliary Obstruction
• Decreased cardiac function
• Disease of liver
• Disorder of electrolytes
• Disorder of lung
• Hypoxia
• Kidney disease
• Myasthenia gravis
• Obesity
• Renal failure syndrome

Mechanism & targets

• Established pharmacologic class: Nondepolarizing Neuromuscular Blocker

Molecular targets (3)

Target	Gene	Action	Activity
Neuronal acetylcholine receptor; alpha4/beta2	CHRNB2|CHRNA4	unknown	IC50 8.26
Acetylcholine receptor	CHRNA1|CHRNB1|CHRND	antagonist	IC50 8.20
Acetylcholine receptor; alpha1/beta1/delta/gamma	CHRNA1|CHRNG|CHRNB1|CHRND	unknown	IC50 7.09

Regulatory approvals (1)

Date	Agency	Marketed as	Applicant	Orphan
1972-10-24	FDA	—	—

ATC classification

ATC code	Therapeutic hierarchy
M03AC01	MUSCULO-SKELETAL SYSTEM › MUSCLE RELAXANTS › MUSCLE RELAXANTS, PERIPHERALLY ACTING AGENTS › Other quaternary ammonium compounds

Reported adverse-event signals

Strongest FDA FAERS disproportionality signals (log-likelihood ratio). A signal is a statistical association in spontaneous reports, not proof that the drug causes the event.

MedDRA term	LLR
Labile blood pressure	240.7
Hepatic ischaemia	145.2
Haematemesis	118.2
Hepatorenal syndrome	116.0
Renal failure	99.9
Coagulopathy	98.3

Chemical structure

• Molecular formula: C₃₅H₆₀N₂O₄
• Molecular weight: 572.87 g/mol
• CAS number: 15500-66-0
• InChIKey: GVEAYVLWDAFXET-XGHATYIMSA-N
• PubChem CID: 441289

CC(=O)O[C@H]1[C@H](C[C@H]2[C@@H]3CC[C@H]4C[C@H](OC(C)=O)[C@H](C[C@]4(C)[C@H]3CC[C@]12C)[N+]1(C)CCCCC1)[N+]1(C)CCCCC1

Frequently asked questions

Answers are generated from the structured data on this page, not written by hand.

What is Pancuronium used for?

DrugCentral lists the following indications for Pancuronium: General anesthesia, Muscle relaxation, function and Skeletal Muscle Relaxation for Endotracheal Intubation.

How does Pancuronium work?

Its molecular targets in DrugCentral include CHRNB2|CHRNA4, CHRNA1|CHRNB1|CHRND (antagonist) and CHRNA1|CHRNG|CHRNB1|CHRND.

When was Pancuronium first approved?

Pancuronium was first approved by the FDA in 1972.

What drug class does Pancuronium belong to?

Pancuronium is in the Nondepolarizing Neuromuscular Blocker class.

What is the chemical formula of Pancuronium?

Pancuronium has the molecular formula C35H60N2O4 and a molecular weight of 572.87 g/mol.

Sources

• DrugCentral drug card 2052 — structure, indications, targets, approvals, pharmacologic classes (CC BY-SA 4.0)
• ChEMBL CHEMBL1200757 — compound record and bioactivity
• PubChem CID 441289 — chemical identifiers
• DrugBank DB01337 — drug record
• FDA UNII J76UF062FS — substance identity
• DailyMed: FDA labels for Pancuronium — current prescribing information (label search)
• FDA Adverse Event Reporting System (openFDA FAERS) — adverse-event signals, as aggregated by DrugCentral

How this page is built: methodology · editorial policy & corrections.